期刊文献+

三种抗菌药物治疗非淋菌性宫颈炎成本-效果分析 被引量:4

Analysis of the cost-effect of three types of antibiotics in the treatment of nongonococcal cervicitis
下载PDF
导出
摘要 目的探讨三种不同类型抗菌药物治疗非淋菌性宫颈炎的药物经济学效果。方法 120例非淋菌性宫颈炎患者随机分成A、B、C三组,每组40例,分别给予美他环素、克拉霉素、司帕沙星治疗,运用药物经济学方法比较其成本-效果。结果 A、B、C三组总有效率分别为80.0%,90.0%,82.5%,成本-效果比分别为0.21,0.23,0.55。结论治疗非淋菌性宫颈炎以B组方案为较佳治疗方案。 Objective To explore pharmacoeconomic effects of three different types of antibiotics in the treatment of nongonococcal cervicitis. Methods A total of 120 cases of nongonococcal cervieitis were randomly divided into group A (40 cases), group B (40 cases) and group C (40 cases). Group A was given metacycline, and group B was given clarithromycin, while group C was treated by sparfloxacin. Pharmacoeconomic method was applied to compare the cost - effect of the three groups. Results The total effective rates of the three groups were 80.0%, 90.0%, and 82.5%. The ratios of cost-effect were 0.21, 0.23, and 0.55. Conclusion The treatment of group B is the best therapeutic scheme for nongonococcal cervicitis.
出处 《中国现代药物应用》 2014年第18期14-15,共2页 Chinese Journal of Modern Drug Application
关键词 成本-效果 药物经济学 支原体 Cost-effect Pharmacoeconomics Mycoplasma
  • 相关文献

参考文献5

二级参考文献34

共引文献55

同被引文献25

  • 1郑劲平,康健,蔡柏蔷,周新,曹兆龙,白春学,钟南山.吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效与安全性比较[J].中华结核和呼吸杂志,2006,29(6):363-367. 被引量:159
  • 2Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summarywww, goldeop- deom. update [J]. Am J Respir Crit Care Med, 2013, 187(4) : 347-365.
  • 3Lopez AD, Murray CC. The global burden of disease, 1990- 2020 [J]. Nat Med, 1998, 4(11): 1241-1243.
  • 4Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease ( Revised 2011 ) [ C]. GOLD Executive Committee 2011.
  • 5Gani R, Griffin J, Kelly S, et al. Economic analyses compa- ring tiotropium with ipratropium or salmeterol in UK patients with COPD[J]. Prim Care Respir J, 2010, 19(1) : 68-74.
  • 6Maureen PMH, Rutten-van M. Jan 130, etal. Brigitta U. M. Modelling the 5-year cost effectiveness of tiotropium, salmet- erol and ipratropium for the treatmefit of chronic obstructive pulmonary disease in Spain[J]. Eur J Health Econ, 2007, 8 (2) : 123-135.
  • 7Hettle R, Wouters H, Ayres J, et al. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium[J]. Respir Med, 2012, 106(12): 1722-1733.
  • 8Price D, Gray A, Gale R. et al. Cost-utility analysis of inda- caterol in Germany: A once-daily maintenance bronchodilator for patients with COPD[J]. Respir Med, 2011, 105 (11): 1635-1647.
  • 9Wang S, Peng L, Li J, et al. A Trial-Based Cost-Effective- ness Analysis of Erlotinib Alone versus Platinum-Based Dou- blet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non-Small-Cell Lung Cancer [J]. PloS One, 2013, 8(3): 1-9.
  • 10孟丽丽.康妇特栓联合微波治疗慢性宫颈炎临床研究[J].中国药物经济学,2013,18(6):218-219.

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部